SLNSW-Bipolar androgen therapy in men with metastatic c...-TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5875180

Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study

Full title: Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study

Author/creator: Teply, Benjamin A, Wang, Hao, Luber, Brandon, Sullivan, Rana, Rifkind, Irina, Bruns, Ashley, Spitz, Avery, DeCarli, Morgan, Sinibaldi, Victoria, Pratz, Caroline F, Lu, Changxue, Silberstein, John L, Luo, Jun, Schweizer, Michael T, Drake, Charles G, Carducci, Michael A, Paller, Channing J, Antonarakis, Emmanuel S, Eisenberger, Mario A, Denmeade, Samuel R.

Call Numbers:

Record Identifier: TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5875180

Language: English

Formats: Articles

Publishers: England: Elsevier Ltd

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5875180

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study

    Record identifier

    TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5875180

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5875180

    Share

    Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5875180

    Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study

    Full title

    Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study

    Author / Creator

    Teply, Benjamin A ; Wang, Hao ; Luber, Brandon ; Sullivan, Rana ; Rifkind, Irina ; Bruns, Ashley ; Spitz, Avery ; DeCarli, Morgan ; Sinibaldi, Victoria ; Pratz, Caroline F ; Lu, Changxue ; Silberstein, John L ; Luo, Jun ; Schweizer, Michael T ; Drake, Charles G ; Carducci, Michael A ; Paller, Channing J ; Antonarakis, Emmanuel S ; Eisenberger, Mario A ; Denmeade, Samuel R

    Publisher

    England: Elsevier Ltd

    Journal title

    The lancet oncology, 2018, Vol.19 (1), p.76-86

    Record Identifier

    TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5875180

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    Aged Aged, 80 and over Analysis Androgens Androgens - administration & dosage Androgens - adverse effects Antiandrogens Antineoplastic Agents, Hormonal - administration & dosage Antineoplastic Agents, Hormonal - adverse effects Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Apoptosis Asymptomatic Baltimore Bone lesions Cancer Cancer therapies Castration Cell division Chemotherapy Clinical trials Deoxyribonucleic acid Development and progression Disease Progression DNA Drug dosages Embolism Gallstones Gene amplification Gonadotropin-Releasing Hormone - agonists Gonadotropin-Releasing Hormone - metabolism Hepatitis Hormones Humans Hypotheses Kallikreins - blood Male Mens health Metastases Metastasis Middle Aged Myocardial infarction Neoplasm Metastasis Nuclear medicine Oncology Oncology, Experimental Pain Patients Phenylthiohydantoin - administration & dosage Phenylthiohydantoin - adverse effects Phenylthiohydantoin - analogs & derivatives Prostate cancer Prostate-specific antigen Prostate-Specific Antigen - blood Prostatic Neoplasms, Castration-Resistant - blood Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - pathology Sepsis Studies Testosterone Testosterone - administration & dosage Testosterone - adverse effects Testosterone - analogs & derivatives Testosterone - blood Time Factors Treatment Outcome Tumors

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5875180

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5875180

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    View in old catalogue

    Connecting people and collections